A New Approach to Type 2 Diabetes

We’re focused on transforming the treatment of metabolic diseases to improve the lives of patients

Type 2 diabetes is a metabolic disease. This means that the disease affects how the body turns food into energy and disrupts the ability of the body to appropriately regulate levels of sugar in the blood. Elevations in blood sugar that result from a prolonged period of diabetes can lead to life-threatening problems, including heart disease, kidney disease, and nerve damage.

Traditionally, type 2 diabetes treatments have focused on managing the symptoms of the disease, but treating the symptoms alone does not prevent the disease from worsening steadily. Because type 2 diabetes keeps progressing, many patients require more treatments to be added over time to try to control their blood sugar. Eventually, patients may even require insulin therapy to treat their disease.

We believe that fundamentally new therapeutic approaches are needed to address an important root cause of type 2 diabetes, insulin resistance, in a way that is durable and effective in the real world, not just in the clinical lab.

With our patients’’ long-term wellbeing as our North Star, we are dedicated to developing therapies that contribute to better metabolic health rather than disease management alone.


Only 50 percent of type 2 diabetes patients who use insulin are well-controlled, that is, at their target blood sugar level. For people with advanced type 2 diabetes who have inadequate control of their disease despite lifestyle intervention and drug therapy and yet are also on long-acting insulin therapy, the main form of therapy to control HbA1c today is insulin dose escalation. But higher insulin dosages have diminishing effects on blood sugar, and they bring greater risk of side effects, including hypoglycemia (dangerously low blood sugar) and weight gain. Higher insulin doses are associated with more morbidity and higher rates of hospitalization.


We are now enrolling patients with type 2 diabetes who are uncontrolled on long-acting insulin therapy in our Revitalize-1 clinical studies (NCT #04419779). Revitalize-1 will assess the potential of outpatient Revita DMR® treatment to improve blood sugar control and help to eliminate patients’ need for long-acting insulin.

Revitalize-1 is a prospective, randomized, double-blind, crossover, sham-controlled study that is expected to enroll more than 500 patients across 35 sites in the United States and Europe.

To learn more about the study and determine if you might be eligible to participate, visit revitastudy.com.

Learn More

You are now leaving the Fractyl.com website

You are leaving Fractyl’s main website to go to Fractyl’s U.K. site.

By selecting Continue you will be directed to Fractyl’s U.K. site. If you would like to remain on Fractyl’s main site, select the Cancel button.